Trial record 1 of 1 for:    NCT01422265
Previous Study | Return to List | Next Study

Patient Reported Symptoms in Ovarian Cancer (PRECISION)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Genentech
ClinicalTrials.gov Identifier:
NCT01422265
First received: August 22, 2011
Last updated: July 7, 2014
Last verified: July 2014
  Purpose

This multicenter, observational, prospective study will include approximately 20 US-based centers, and approximately 142 patients diagnosed with epithelial ovar ian cancer, primary peritoneal carcinoma or fallopian tube carcinoma, whose dise ase has recurred > 6 months after first-line platinum-based chemotherapy (first recurrence). Patients who have completed second-line chemotherapy and are curren tly in observation or undergoing bevacizumab maintenance treatment will be eligi ble to participate in the study.


Condition
Ovarian Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Patient Reported Symptoms in Ovarian Cancer

Resource links provided by NLM:


Further study details as provided by Genentech:

Primary Outcome Measures:
  • Change in MD Anderson Symptom Inventory-Ovarian Cancer (MDASI-OC) sub-set symptom severity score before and after disease progression [ Time Frame: Up to 9 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • MDASI-OC Symptom Severity Score [ Time Frame: Up to 9 months ] [ Designated as safety issue: No ]
  • MDASI-OC Symptom Interference Score [ Time Frame: By month 9 ] [ Designated as safety issue: No ]
  • HRQoL scores [ Time Frame: Up to 9 months ] [ Designated as safety issue: No ]

Enrollment: 56
Study Start Date: June 2011
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with platinum-sensitive ovarian cancer in maintenance phase of second-line treatment

Criteria

Inclusion Criteria:

  • Histologically documented ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma that has recurred > 6 months after platinum-based chemotherapy
  • This must be the first recurrence of the epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma
  • Are at least two weeks but no more than 3 months after the completion of second-line cytotoxic chemotherapy
  • Are currently under observation or being treated with bevacizumab as a second-line maintenance therapy
  • Have a valid email address and access to the internet
  • Provide voluntary written informed consent
  • Speak and read English fluently

Exclusion Criteria:

  • Current participation in a blinded clinical trial for ovarian cancer treatment. (Participation in a trial involving only supportive care medicines and/or growth factors is acceptable)
  • Another primary diagnosis of cancer in a different site
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01422265

  Hide Study Locations
Locations
United States, Arizona
Goodyear, Arizona, United States, 85338
Phoenix, Arizona, United States, 85013
Tucson, Arizona, United States, 85724
United States, California
Salinas, California, United States, 93901
Whittier, California, United States, 90603
United States, Colorado
Englewood, Colorado, United States, 80113
United States, Connecticut
Farmington, Connecticut, United States, 06030
New Britain, Connecticut, United States, 6052
United States, Georgia
Augusta, Georgia, United States, 30912
United States, Illinois
Hinsdale, Illinois, United States, 60521
Joliet, Illinois, United States, 60435
Skokie, Illinois, United States, 60076
United States, Indiana
Indianapolis, Indiana, United States, 46202
Indianapolis, Indiana, United States, 46260
United States, Maryland
Baltimore, Maryland, United States, 21237
Cumberland, Maryland, United States, 21502
United States, Montana
Missoula, Montana, United States, 59802
United States, Nebraska
Lincoln, Nebraska, United States, 68510
United States, New York
Buffalo, New York, United States, 14263-0001
New York, New York, United States, 10021
Watertown, New York, United States, 57201
United States, Ohio
Canton, Ohio, United States, 44718
Cleveland, Ohio, United States, 44106-5067
Columbus, Ohio, United States, 43212
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19124
Pittsburgh, Pennsylvania, United States, 15213
United States, Tennessee
Chattanooga, Tennessee, United States, 37403
United States, Utah
Salt Lake City, Utah, United States, 84132-0001
United States, Virginia
Annandale, Virginia, United States, 22003
United States, Washington
Tacoma, Washington, United States, 98405
Sponsors and Collaborators
Genentech
Investigators
Study Director: Clinical Trials Genentech
  More Information

No publications provided

Responsible Party: Genentech
ClinicalTrials.gov Identifier: NCT01422265     History of Changes
Other Study ID Numbers: ML28066, 130/070
Study First Received: August 22, 2011
Last Updated: July 7, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders

ClinicalTrials.gov processed this record on July 23, 2014